Episode 89: Potential of CNM-Au8 Gold Nanocrystals to Treat ALS
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Berry, MD, PhD. [LISTEN TIME: 14 minutes]
Episode 89 of the NeurologyLive®
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 89, "Potential of CNM-Au8 to Treat ALS," features an exclusive interview with James Berry, MD, PhD, director of the Massachusetts General Hospital ALS Care Center. At the 2023 American Academy of Neurology Annual Meeting, he spoke about new data from a study assessing CNM-Au8, a nanocrystal formulation in development for patients with ALS. Additionally, he talked about the current unmet needs in the ALS community, including the need for more diverse treatment options and increased research.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Approves Brexpiprazole as First Therapy for Alzheimer Agitation FDA Panel Votes in Favor of Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy in Tight Decision Alzheimer Agent COYA 301 Halts Cognitive Decline, Restores Regulatory T Cell Dysfunction in Phase 1 Study Phase 2 Data Highlight Fenebrutinib's Impact on Brain Lesions in Relapsing Multiple Sclerosis
EPISODE BREAKDOWN
- 1:15 – Clinical development program of CNM-Au8
- 3:40 – Safety findings, treatment responses of CNM-Au8
- 4:20 – Next steps in research
- 6:25 – Neurology News Minute
- 8:45 – Conducting safe trials
- 10:00 – Remaining unmet needs for patients with ALS
- 11:15 – Need for additional research
Hoping to listen on your favorite podcast app? See below:
REFERENCES
1. Berry J, Maragakis N, Paganoni S, et al. Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations. Presented at: 2023 AAN Annual Meeting; April 22-27, Boston, Massachusetts.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
Perispinal Etanercept Shows No Efficacy in Treating Chronic StrokeSeptember 16th 2025
